IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories share news and announcements
771 announcements, routine notices left out, newest first. Page 13 of 16.
Jul 2011
11 Jul · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2011.
Jun 2011
15 Jun · Meeting
Annual General Meeting of the Company will be held on July 28, 2011. The Register of Members and Share Transfer Books of the Company will remain closed from July 20, 2011 to July 28, 2011, both days inclusive for the purpose of Annual General Meeting and for the entitlement of final dividend @ Re.1.20 per share (60%) which if sanctioned will be paid on or before August 20, 2011.
May 2011
25 May · Dividend
Board of Directors of the Company at its meeting held on May 24, 2011 has recommended a final dividend of Rs. 1.20/- per share (60%) for the financial year ended March 31, 2011.13 May · Board meeting
Inter-alia, to consider : (1) The Audited Financial Results for the financial year ended March 31, 2011; and (2) Recommendation of final dividend for the financial year ended March 31, 2011.
Apr 2011
Mar 2011
9 Mar · Updates
Company's new formulations manufacturing unit situated at Pharma zone, SEZ Indore, Pithampur, Madhya Pradesh has been inspected and certified that it complies with the principles and guidelines of Good Manufacturing Practices laid down in the directives by the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K. It is the fourth manufacturing unit of the Company to have received such approval from MHRA, U.K.
Jan 2011
25 Jan · Business
At the meeting of the Board of Directors of the Company held on January 25, 2011, 1,25,000 fully paid-up equity shares of Rs.2/- each of the Company @ Rs.63/- per equity share have been allotted upon exercise of options by allottees to whom options were granted on October 29, 2007 and November 11, 2008 pursuant to Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs.25,14,12,810/- divided into 12,57,06,405 fully paid-up equity shares of Rs.2/- each.25 Jan · Dividend
Board of Directors of the Company, at its meeting held on January 25, 2011, has declared 2nd interim dividend of Re. 1/- per share (50%) for the financial year 2010-11.12 Jan · Dividend
Interim dividend if declared shall be paid / dispatched on February 18, 2011.12 Jan · Board meeting
Inter-alia, to consider the following : (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2010; (2) 2nd Interim Dividend for the financial year 2010-11; (3) Allotment of equity shares on exercise of options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2006 (ESOS).12 Jan · Corporate action
Company has fix February 02, 2011 as the 'Record Date' for the Members entitlement of 2nd interim dividend for the financial year 2010-11.
Oct 2010
22 Oct · Business
At the meeting of the Board of Directors of the Company held on October 22, 2010, 3,53,750 equity shares of Rs. 2/- each of the Company have been allotted @ Rs. 40/- per equity share upon exercise of options by allottees to whom options were granted on September 23, 2006 under Ipca Laboratories Limited - Employee Stock Option Scheme 2006 (ESOS). The Equity shares now allotted would rank pari-passu in all respects with the existing paid-up equity share capital of the Company. With this allotment, the paid up equity share capital of the Company is now increased to Rs. 25,11,62,810/- divided into 12,55,81,405 fully paid-up equity shares of Rs. 2/- each.22 Oct · Dividend
Board of Directors of the Company at its meeting held on October 22, 2010, have declared an interim dividend of 50% (Re. 1/- per share) for the financial year 2010-11.7 Oct · Corporate action
Company has fix October 29, 2010 as the 'Record Date' for the entitlement of interim dividend for the financial year 2010-11.7 Oct · Board meeting
Inter-alia, to consider the following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2010; and (2) Interim Dividend for the financial year 2010-11.
Aug 2010
2 Aug · Meeting
Members of the Company at the Annual General Meeting held on July 29, 2010 have accorded their approval for the following : (1) Adoption of Balance Sheet of the Company as on March 31, 2010 and Profit & Loss Account for the year ended on that date and reports of the Directors and Auditors thereon; (2) Payment of dividend on the equity shares; (3) Re-appointment of Mr. Premchand Godha, Mr.R.S.Hugar and Mr.Babulal Jain as the Directors of the Company; (4) Re-appointment of Mr.Natvarlal Vepari & Co, Chartered Accountants as the Auditors of the Company to hold office till the conclusion of the next Annual General Meeting; (5) Appointment of Mr. Anand T. Kusre as a Director of the Company.
Jul 2010
31 Jul · Management
At the meeting of the Board of Directors of the Company held on July 29, 2010, the Board has re-designated the incumbent Executive Director, Mr. A.K. Jain as the Joint Managing Director of the Company. The other terms and conditions of his appointment including the remuneration payable to him as earlier approved by the shareholders of the company, however, shall remain unchanged.
Jun 2010
29 Jun · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2010.
May 2010
28 May · Meeting
Annual General Meeting of the Company will be held on July 29, 2010. The Register of Members and Share Transfer Books of the Company will remain closed from July 20, 2010 to July 29, 2010, both days inclusive for the purpose of Annual General Meeting and for the entitlement of final dividend @ Re.1 per equity share (50%).28 May · Dividend
Board at its meeting held on May 28, 2010, has recommended a final dividend of Re. 1/- per share for the financial year ended March 31, 2010.10 May · Board meeting
Inter alia, to consider (1)The Audited Financial Results for the financial year ended March 31, 2010; and (2) recommendation of final dividend for the financial year ended March 31, 2010.
Apr 2010
7 Apr · Results
Ipca Laboratories Ltd. has informed the Exchange that it has been decided by the Company to publish its Audited Financial Results for the financial year ended March 31, 2010 on or before June 30, 2010.
Feb 2010
25 Feb · Corporate action
Ipca Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at their meeting held on February 25, 2010 have decided to fix March 23, 2010, as the 'Record Date' for the Members entitlement of sub-divided shares. Each fully paid-up equity share of Rs.10/- each of the Company is being sub-divided into 5 fully paid-up equity shares of Rs.2/- each.25 Feb · Meeting
Ipca Laboratories Ltd. has informed the Exchange vide its letter dated February 25, 2010 that "The members of the Company at their Extraordinary General Meeting held today have accorded their approval for the following: (1) Sub-division of each of the existing Equity Share having face value of Rs.10/- each (Rupees Ten only) into 5 (Five) equity shares of Rs.2/- (Rupees Two only) each; (2) Alteration in Clause V of the Memorandum of the Association to read as "The Authorised Share Capital of the Company is Rs.45,00,00,000/- (Rupees Forty Five Crores) divided into 22,50,00,000 (Twenty Two Crores Fifty Lacs) Equity Shares of Rs.2/- (Rupees Two) each".12 Feb · Board meeting
Inter alia, to fix the ' Record Date' for deciding the Members entitlement of sub-divided shares.3 Feb · Meeting
Ipca Laboratories Ltd. has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the members of the Company scheduled to be held on February 25, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
21 Jan · Management
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on January 21, 2010, Mr. Anand T. Kusre has been appointed as a Director of the Company. Mr. Kusre has been inducted as a member of the Audit Committee and Remuneration & Compensation Committee of the Board. Further the composition of the Board of Directors shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Allotment of Equity Shares
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on January 21, 2010, 14,250 fully paid up equity shares of Rs. 10/- each of the Company @ Rs. 315/- per equity shares have been allotted upon exercise of options by allottees to whom options were granted on November 11, 2008 pursuant to IPCA Laboratories Limited- Employee Stock Option Scheme 2006 (ESOS). Further the Equity shares now allotted would rank pari-passu in all respects with existing paid-up equity share Capital of the Company. With this allotment the paid up equity share capital of the Company is now increased to Rs. 25,04,55,310/- divided into 2,50,45,531 fully paid-up equity shares of Rs. 10/- each.21 Jan · Dividend
Ipca Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at their meeting held on January 21, 2010 has declared 2nd interim dividend of Rs.4/- per share (40%) for the financial year 2009-10. Further, the Board has also announced stock split of 5 equity shares of Rs. 2/- each for every 1 equity share of Rs.10/- each, subject to the approval of the members of the Company in the ensuing Extraordinary General Meeting.21 Jan · Business
Ipca Laboratories Ltd. has informed the Exchange regarding a press release dated January 21, 2010, titled "Ipca Laboratories Q3 FY10 Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Jan · Board meeting
Inter-alia, to consider the following: (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2009. (2) 2nd Interim Dividend for the financial year 2009-10. (3) Allotment of equity shares on exercise of options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2006 (ESOS); and (4). Sub-division (share split) of the equity shares of the Company. Further, the Company has decided to fix January 28, 2010, as the 'Record Date' for the Members entitlement of 2nd Interim dividend for the financial year 2009-10 that may be declared at the said Board Meeting.
Dec 2009
16 Dec · Updates
Ipca Laboratories Ltd. has informed the Exchange regarding Ipca's anti-malarial fixed dose combination formulation - Artemether + Lumefantrine pre-qualified by WHO. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Dec · Allotment of Equity Shares
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on December 10, 2009, 95,500 equity shares of Rs. 10/- each of the Company have been allotted. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Dec · Demise of Director
Ipca Laboratories Ltd. has informed the Exchange about the sudden demise of Mr.V.A.Gore, Independent Director on the Board of Directors of the Company on December 02, 2009. Mr.Gore was also a member of the Audit Committee and Remuneration & Compensation Committee of the Board of Directors of the Company. The Board of Directors and all Ipcaites place on record their sincere appreciation for the services rendered by him during his tenure as a Director of the Company.1 Dec · Board meeting
Inter-alia, to consider the allotment of equity shares on exercise of options under Ipca Laboratories ltd.- Employees Stock Option Scheme - 2006 (ESOS).
Nov 2009
12 Nov · Post offer Public announcement
Imperial Corporate Finance & Services Pvt. Ltd. has submitted to the Exchange a Post Offer Public Announcement ("Post PA") dated November 10, 2009 released in newspaper on November 11, 2009 pursuant to Regulation 19(7) of the Buyback Regulations, with respect to Buy-back of Equity Shares by Ipca Laboratories Ltd from the "Open Market" Purchase through Stock Exchanges in compliance with Securities and Exchange Board of India (Buy Back of Securities) Regulations, 1998 ("Buyback Regulations"), Public Announcement ("PA") dated November 24, 2008 and Corrigendum to PA dated December 8, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Nov · Extinguishment
Ipca Laboratories Ltd. has informed the Exchange that 2,56,219 equity shares of Rs. 10/- have been extinguished till October 31, 2009. Of the above, Nil equity shares of Rs. 10/- each have been extinguished during the month of October 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Nov · Closure of Buy back
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on November 03, 2009, it has been decided to close from the close of trading hours on bourses on November 10, 2009, the on-going Buy-back program of the Company to buy-back its own fully paid-up equity shares through open market purchase.
Oct 2009
28 Oct · Board meeting
Inter-alia, to consider closure of the on-going Buy-back of own fully paid equity shares of the Company from open market purchase through Stock Exchanges.